



INCOME ANALYSIS




TOTAL OPERATIONAL REVENUE*
\$3,187,832

TOTAL EXPENSES
\$2,911,725

EXPENSE ANALYSIS



PROGRAM RATIO



*Above chart excludes net investment losses of \$5,773,600

Net Assets = \$46,824,384, mainly attributable to proceeds from the 2021 sale of the Priority Review Voucher (PRV) issued after FDA approval of lonafamib as a treatment for Progeria. PRF's 10-year average net assets prior to this historic payment = \$4.63 million.